ReviewNature reviews. Rheumatology2012
The pathogenesis of rheumatoid arthritis: new insights from old clinical data?
Review in Nature reviews. Rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritis.EBioMedicine · 2019Pooled it
- The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.Annals of the rheumatic diseases · 2015Trial
- Changes in Blood Cells and Complements During Relapse Prevention Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder.International journal of molecular sciences · 2026Article
- Poor prognostic factors and unmet needs in rheumatoid arthritis.Rheumatology (Oxford, England) · 2025Review
- Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.Annals of the rheumatic diseases · 2024Review
- Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases.Stem cells international · 2022Review
- Article
- Interleukin 27 Signaling in Rheumatoid Arthritis Patients: Good or Evil?Frontiers in immunology · 2021Review
- Anti-Carbamylated LL37 Antibodies Promote Pathogenic Bone Resorption in Rheumatoid Arthritis.Frontiers in immunology · 2021Article
- Stimuli-responsive polymeric nanomaterials for rheumatoid arthritis therapy.Biophysics reports · 2020Article
- Wasp Venom Possesses Potential Therapeutic Effect in Experimental Models of Rheumatoid Arthritis.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- General synovitis score and immunologic synovitis score reflect clinical disease activity in patients with advanced stage rheumatoid arthritis.Scientific reports · 2019Article
- Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.Drug design, development and therapy · 2019Review
- Rheumatoid Synovial Fluids Regulate the Immunomodulatory Potential of Adipose-Derived Mesenchymal Stem Cells Through a TNF/NF-κB-Dependent Mechanism.Frontiers in immunology · 2019Article
- Targeting Mesenchymal Stromal Cells/Pericytes (MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid Arthritis.Frontiers in immunology · 2019Review
- Taxol alleviates collagen-induced arthritis in mice by inhibiting the formation of microvessels.Clinical rheumatology · 2019Article
- Control of articular synovitis for bone and cartilage regeneration in rheumatoid arthritis.Inflammation and regeneration · 2018Review
- 4-(Hydroxymethyl)catechol Extracted From Fungi in Marine Sponges Attenuates Rheumatoid Arthritis by Inhibiting PI3K/Akt/NF-κB Signaling.Frontiers in pharmacology · 2018Article
- Interleukin-10-producing LAG3Arthritis research & therapy · 2017Article
- Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker.Arthritis research & therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite their different targets, biologic agents used for blockade of TNF and IL-6, inhibition of T-cell co-stimulation and B-cell depletion all have similar beneficial effects on the outcome of rheumatoid arthritis (RA). This observation raises questions as to whether the targets of these therapies might all be involved in a common pathogenetic pathway. However, blockade of TNF and IL-6 has a similar inhibitory effect on joint damage progression in patients with either early or late disease. In comparison, B-cell depletion and inhibition of T-cell co-stimulation seem to have a somewhat delayed effect on joint damage (compared with cytokine inhibition), which suggests that these approaches affect upstream pathogenetic events. This article discusses these disparities and presents hypotheses as to whether clinical trial data can be used to determine at which point a biologic agent might interfere with the pathogenetic cascade in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.